GE9:F:F-Genmab A/S (EUR)

COMMON STOCK | |

Last Closing

USD 243.9

Change

+0.90 (+0.37)%

Market Cap

USD 15.01B

Volume

20.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-24 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
NNND:F Tencent Holdings Ltd

-0.53 (-1.16%)

USD 432.12B
MATA:F Panasonic Corporation

N/A

USD 20.38B
1CK:F CK Asset Holdings Limited

-0.08 (-2.23%)

USD 12.56B
AD5B:F Adevinta ASA

N/A

USD 12.23B
0PY:F Paycom Soft

+1.70 (+1.30%)

USD 7.68B
KMBA:F SK TELECOM CO.LTD.ADR 5/9

-0.40 (-2.11%)

USD 7.37B
UIPN:F Unipol Gruppo Finanziario Spa

-0.09 (-0.96%)

USD 6.37B
2U4:F HICL Infrastructure PLC

-0.01 (-0.69%)

USD 2.72B
CLN:F The City of London Investment ..

-0.03 (-0.50%)

USD 1.94B
R7I:F RENEWABLES INFRASTRUCTURE

-0.01 (-0.89%)

USD 1.74B

ETFs Containing GE9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.14% N/A N/A 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.14% N/A N/A 23% F
Trailing 12 Months  
Capital Gain -30.39% N/A N/A 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.39% N/A N/A 20% F
Trailing 5 Years  
Capital Gain 54.61% N/A N/A 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.61% N/A N/A 58% F
Average Annual (5 Year Horizon)  
Capital Gain 14.43% N/A N/A 80% B-
Dividend Return 14.43% N/A N/A 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.92% N/A N/A 37% F
Risk Adjusted Return 45.21% N/A N/A 69% C-
Market Capitalization 15.01B N/A N/A 90% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike